We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

44 hedge funds and large institutions have $3.39M invested in Oncolytics Biotech in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

7% more funds holding

Funds holding: 41 → 44 (+3)

0.11% less ownership

Funds ownership: 2.04% → 1.93% (-0.11%)

12% less capital invested

Capital invested by funds: $3.87M → $3.39M (-$474K)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

Holders
44
Holders Change
+3
Holders Change %
+7.32%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
10
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$289K
2
TD Asset Management
TD Asset Management
Ontario, Canada
+$159K
3
VF
Virtu Financial
New York
+$109K
4
Two Sigma Investments
Two Sigma Investments
New York
+$77.2K
5
Renaissance Technologies
Renaissance Technologies
New York
+$70.4K

Top Sellers

Rank Fund Capital Flow
1
Creative Planning
Creative Planning
Kansas
-$648K
2
IAIM
International Assets Investment Management
Florida
-$355K
3
Citadel Advisors
Citadel Advisors
Florida
-$61.2K
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$60.8K
5
Squarepoint
Squarepoint
New York
-$44K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
1
JP Morgan Chase
New York
$919K +$289K +94,390 +168%
IAIM
2
International Assets Investment Management
Florida
$448K -$355K -116,026 -42%
ARC
3
Advisor Resource Council
Texas
$280K +$309K +101,000 New
Two Sigma Advisers
4
Two Sigma Advisers
New York
$252K -$5.82K -1,900 -2%
CIBC World Market
5
CIBC World Market
Ontario, Canada
$172K -$159 -52 -0.1%
Bank of America
6
Bank of America
North Carolina
$137K -$39.6K -12,940 -21%
Morgan Stanley
7
Morgan Stanley
New York
$128K -$14.4K -4,700 -9%
TD Asset Management
8
TD Asset Management
Ontario, Canada
$120K +$159K +52,007 New
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$102K +$28.4K +9,271 +34%
VF
10
Virtu Financial
New York
$98K +$109K +35,425 New
Citadel Advisors
11
Citadel Advisors
Florida
$81K -$61.2K -19,989 -40%
Two Sigma Investments
12
Two Sigma Investments
New York
$70K +$77.2K +25,200 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$67K – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$64K +$70.4K +23,000 New
UBS Group
15
UBS Group
Switzerland
$57K +$56.9K +18,577 +880%
BAM
16
Brave Asset Management
New Jersey
$55K +$30.6K +10,000 +100%
Bank of Montreal
17
Bank of Montreal
Ontario, Canada
$46K +$14.4K +4,711 +40%
LPL Financial
18
LPL Financial
California
$33K -$1.69K -550 -4%
Comerica Bank
19
Comerica Bank
Texas
$32K – – –
BCV
20
Banque Cantonale Vaudoise
Switzerland
$31K – – –
CGA
21
Crescent Grove Advisors
Illinois
$28K – – –
CCM
22
Chiron Capital Management
Florida
$28K +$613 +200 +2%
CMA
23
Cedar Mountain Advisors
Oregon
$16K – – –
Rockefeller Capital Management
24
Rockefeller Capital Management
New York
$15K – – –
DI
25
Disciplined Investments
Oklahoma
$14K – – –
1
2

ONCY Hedge Fund Activity: Q2 2021 in Review

44 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q2 2021, worth a combined $3.39M — down 12% from $3.87M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ONCY positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 10 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $289K. The largest seller was Creative Planning, exiting entirely with an estimated $648K sold.

  • 44 institutional investors held Oncolytics Biotech (ONCY) as of Q2 2021, up from 41 in Q1 2021.
  • Funds reported $3.39M of Oncolytics Biotech stock for Q2 2021, down 12% quarter-over-quarter.
  • 8 funds opened new Oncolytics Biotech positions in Q2 2021 and 5 closed out, a net change of +3 holders.
  • The largest Oncolytics Biotech buyer in Q2 2021 was JP Morgan Chase, an estimated $289K added.
  • The largest Oncolytics Biotech seller in Q2 2021 was Creative Planning, an estimated $648K sold.

Based on aggregated 13F filings for Q2 2021.